An assessment of common marmoset (Callithrix jacchus) γ9+ T cells and their response to phosphoantigen in vitro

Cellular Immunology

Volumn 280, Issue 2, 2012, Pages 132-137

  Rowland, Caroline A ^a   Laws, Thomas R ^a   Oyston, Petra C F ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

9 2 T cells; Burkholderia pseudomallei; Immunotherapy; Marmoset; Phosphoantigen

Indexed keywords

ANTIGEN;

ARTICLE; BACTERIUM; BURKHOLDERIA PSEUDOMALLEI; CALLITRICHINAE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; CALLITHRIX; INTERFERON-GAMMA; MALE; ORGANOPHOSPHATES; PHOSPHOPROTEINS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84873495310     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.12.002     Document Type: Article

References (34)

1. Eberl M., Hintz M., Reichenberg A., Kollas A.K., Wiesner J., Jomaa H. Microbial isoprenoid biosynthesis and human [gamma][delta] T cell activation. FEBS Letters 2003, 544(1-3):4-10.
2. Bennouna J., Levy V., Sicard H., Senellart H., Audrain M., Hiret S., Rolland F., Bruzzoni-Giovanelli H., Rimbert M., Galea C., Tiollier J., Calvo F. Phase I study of Bromohydrin pyrophosphate (BrHPP, IPH1101) a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors. Cancer Immunology Immunotherapy 2010, 59(10):1521-1530.
3. Meraviglia S., Eberl M., Vvermijlen D., Todaro M., Buccheri S., Cicero G., La Mendola C., Guggino G., D'Asaro M., Orlando V., Scarpa F., Roberts A., Caccamo N., Stassi G., Dieli F., Hayday A.C. In vivo manipulation of Vγ9Vδ2 T cell with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clinical & Experimental Immunology 2010, 161(2):290-297.
4. Kabelitz D., Wesch D., Pitters E., Zoller M. Characteriztion of tumor reactivity of human Vγ9Vδ2 gamma delta T cells in vitro and in SCID mice in vivo. The Journal of Immunology 2004, 173(11):6767-6776.
5. Wang L., Das H., Kamath A., Bukowski J.F. Human Vγ2Vδ2 T cells produce IFN-γ and TNF-α with an On/Off/On cycling pattern in response to live bacterial products. The Journal of Immunology 2001, 167:6195-6201.
6. Green A.E., Lissina A., Hutchinson S.L., Heweitt R.E., Temple B., James D., Boulter J.M., Price D.A., Sewell A.K. Recognition of nonpeptide antigens by human Vg9Vd2 T cells requires contact with cells of human origin. Clinical & Experimental Immunology 2004, 136:472-482.
7. Oliaro J., Dudal S., Liautard J., Andrault J.B., Liautard J.P., Lafont V. Vγ9Vδ2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella. Journal of Leukocyte Biology 2005, 77(5):652-660.
8. Dieli F., TroyeΓçéBlomberg M., Ivanyi J., Fourni+® J.J., Krensky A.M., Bonneville M., Peyrat M., Caccamo N., Sireci G., Salerno A. GranulysinΓçéDependent killing of intracellular and extracellular Mycobacterium tuberculosis by V+|9/V+|2 T lymphocytes. The Journal of Infectious Diseases 2001, 184(8):1082-1085.
9. Viey E., Fromont G., Escudier B., Morel Y., Da Rocha S., Chouaib S., Caignard A. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. The Journal of Immunology 2005, 174(3):1338-1347.
10. Ali Z., Shao L., Halliday L., Reichenberg A., Hintz M., Jomaa H., Chen Z.W. Prolonged (E)-4-Hydroxy-3-Methyl-But-2-Enyl Pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vγ2Vδ2 T cells in macaques. The Journal of Immunology 2007, 179(12):8287-8296.
11. Shao L., Huang D., Wei H., Wang R.C., Chen C.., Shen L., Zhang W., Jin J., Chen Z.W. Expansion re-expansion and recall-like expansion of Vγ2Vδ2 T cells with enhanced effector function in smallpox vaccination and monkeypox virus infection. The Journal of Virology 2009, JVI.
12. Ali Z., Yan L., Plagman N., Reichenberg A., Hintz M., Jomaa H., Villinger F., Chen Z.W. {gamma}{delta} T cell immune manipulation during chronic phase of simian HIV infection confers immunological benefits. The Journal of Immunology 2009, 183(8):5407-5417.
13. Sicard H., Ingoure S., Luciani B., Serraz C., Fournie J.J., Bonneville M., Tiollier J., Romagne F. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. The Journal of Immunology 2005, 175(8):5471-5480.
14. Abbott D.H., Barnett D.K., Colman R.J., Yamamoto M.E., Schultz-Darken N.J. Aspects of common marmoset basic biology and life history important for biomedical research. Comparative Medicine 2003, 53(4):339-350.
15. Nelson M., Dean R.E., Salguero F.J., Taylor C., Pearce P.C., Simpson A.J.H., Lever M.S. Development of an acute model of inhalational melioidosis in the common marmoset (Callithrix jacchus). International Journal of Experimental Pathology 2011, 92(6):428-435.
16. Simpson A., White N. Aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy 1999, 43(9):2332.
17. Chaowagul W., Chierakul W., Simpson A., Short J.M., Stepniewska K., Maharjan B., Rajchanuvong A., Busarawong D., Limmathurotsakul D., Cheng A.C., Wuthiekanun V., Newton P.N., White N.J., Day N.P., Peacock S.J. Open-label randomised trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintentace therapy of melioidosis. Antimicrobial Agents and Chemotherapy 2005, 49(10):4020-4025.
18. Rajchanuvong A., Chaowagul W., Suputtamngkol Y., Smith M.D., Dance D.A.B., White N.J. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Transactions of the Royal Sciety of Tropical Medicine and Hygiene 1995, 89(5):546-549.
19. Lukashevich I.S., Carrion R.Jr., Salvato M.S., Mansfield K., Brasky K., Zapata J., Cairo C., Goicochea M., Hoosien G.E., Ticer A., Bryant J., Davis H., Hammamieh R., Mayda M., Jett M., Patterson J. Safety, immunogenicity and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26(41):5246-5254.
20. Griffitths G.D., Hornby R.J., Jagger C.P., Brown A.P., Stoten A., Pearce P.C., Scott L., Pritchard D.I. Development of methods to measure humoral immune responses against selected antigens in the common marmoset (Callithrix jacchus) and the effect of pyridostigmine bromide administration. International Immunopharmacology 2006, 6(12):1755-1764.
21. Boëdec A., Sicard H., Dessolin J., Herbette G., Ingoure S., Raymond C., Belmant C., Kraus J.L. Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. The Journal of Medicinal Chemistry. 2008, 51(6):1747-1754.
22. Holden M.T.G., Titball R.W., Peacock S.J., Cerde+|o-T+írraga A.M., Atkins T., Crossman L.C., Pitt T., Churcher C., Mungall K., Bentley S.D., Sebaihia M., Thomson N.R., Bason N., Beacham I.R., Brooks K., Brown K.A., Brown N.F., Challis G.L., Cherevach I., Chillingworth T., Cronin A., Crossett B., Davis P., DeShazer D., Feltwell T., Fraser A., Hance Z., Hauser H., Holroyd S., Jagels K., Keith K.E., Maddison M., Moule S., Price C., Quail M.A., Rabbinowitsch E., Rutherford K., Sanders M., Simmonds M., Songsivilai S., Stevens K., Tumapa S., Vesaratchavest M., Whitehead S., Yeats C., Barrell B.G., Oyston P.C.F., Parkhill J. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(39):14240-14245.
23. Haas W., Pereira P., Tonegawa S. Gamma/delta cells. Annual Review of Immunology 1993, 11(1993):637-685.
24. Huang D., Shen Y., Qiu L., Chen C.Y., Shen L., Estep J., Hunt R., Vasconcelos D., Du G., Aye P., Lackner A.A., Larsen M.H., Jacobs W.R., Haynes B.F., Letvin N.L., Chen Z.W. Immune distribution and localization of phosphoantigen-specific Vγ2Vδ2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infection and Immunity 2008, 76(1):426-436.
25. Gong G., Shao L., Wang Y., Chen C.Y., Huang D., Yao S., Zhan X., Sicard H., Wang R., Chen Z.W. Phosphoantigen-activated Vγ2Vδ2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood 2009, 113(4):837-845.
26. Dieli F., Troye-Blomberg M., Ivanyi J., Jacques Fournie J., Bonneville M., Peyrat M.A., Sireci G., Salerno A. Vg9/Vd2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. European Journal of Immunology 2000, 30:1512-1519.
27. Ottones F., Dornand J., Naroeni A., Liautard J.P., Favero J. Vγ9Vδ2 T cells impair intracellular multiplication of Brucella suis in autologous monocytes through soluble factor release and contact-dependent cytotoxic effect. The Journal of Immunology 2000, 165(12):7133-7139.
28. Jouen-Beades F., Paris E., Dieulois C., Lemeland J.F., Barre-Dezelus V., Marret S., Humbert G., Leroy J., Tron F. In vivo and in vitro activation and expansion of gamma delta T cells during Listeria monocytogenes infection in humans. Infection and Immunity 1997, 65:4267-4272.
29. Poquet Y., Kroca M., Halary F., Stenmark S., Peyrat M.A., Bonneville M., Fournie J.J., Sjostedt A. Expansion of Vγ9Vδ2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infection and Immunity 1998, 66(5):2107-2114.
30. Jomaa H., Feurle J., Kunzmann V., Tony H.P., Herderich M., Wilhelm M. Vγ9Vδ2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunology & Medical Microbiology 1999, 25(4):371-378.
31. Qin G., Zheng J., Ng I.H., Xiang Z., Lam K.T., Mao H., Li, Peiris J.S., Lau Y.L., Tu W. Type 1 responses of human Vg9Vd2 T cells to influenza A viruses. Journal of Virology 2011, 85(19):10109-10116.
32. Santinarand P., Harley V.S., Dance D.A., Drasar B.S., Bancroft G.J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infection and Immunity 1999, 67(7):3593-3600.
33. Elkins K.L., Colombini S.M., Meierovics A.I., Chu M.C., Chou A.Y., Cowley S.C. Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma. Microbes and Infection 2010, 12(1):28-36.
34. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. Journal of Experimental Medicine 1993, 178(6):2243-2247.